Nandrolone vs Pitavastatin
FDA Approved vs FDA Approved
avoid Mechanism-based · 75% Both Nandrolone and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Nandrolone Pitavastatin
Weight 274.40 Da (base) 421.46 Da
Half-life ~6-12 days (decanoate) ~12 hours
Type 19-nortestosterone steroid (C18H26O2) Synthetic statin (C25H24FNO4)
Key Benefits
Nandrolone
01 Significant increases in lean muscle mass with a favorable anabolic-to-androgenic ratio
02 Enhanced collagen synthesis and joint lubrication, reducing joint pain and improving connective tissue integrity
03 Increased bone mineral density through direct osteoblast stimulation
04 Improved nitrogen retention and protein synthesis for accelerated recovery
05 Stimulation of erythropoietin production, increasing red blood cell mass and oxygen delivery
06 Lower androgenic side effects (hair loss, acne, prostate enlargement) compared to testosterone
07 Clinically demonstrated efficacy in treating anemia of chronic renal failure
08 Potential neuroprotective properties observed in preclinical research
Pitavastatin
01 Minimal CYP450 metabolism — does not interact with CYP3A4, making it ideal for users taking multiple compounds
02 Lowest risk of new-onset diabetes among all statins, supported by the LIVES study and J-PREDICT trial data
03 LDL reductions of 38-45% at standard doses (2-4 mg/day)
04 More robust HDL-raising effect (5-15%) compared to other statins in the class
05 12-hour half-life supports convenient once-daily dosing
06 Favorable safety profile with low incidence of muscle-related side effects
07 Compatible with CYP3A4 inhibitors and inducers that would alter levels of other statins
08 Effective at counteracting AAS-induced lipid disturbances without adding to drug interaction burden
Dosing Protocols
Nandrolone
100-200 mg/week (therapeutic) / 1x per week (decanoate) or 2-3x per week (NPP)
TRT Adjunct - Joint Support 50-100 mg/week 1x per week (decanoate)
Therapeutic - Anemia / Wasting 100-200 mg/week 1x per week (decanoate)
Performance Enhancement - Moderate 200-400 mg/week 1x per week (decanoate) or split into 2 injections
NPP Protocol - Shorter Cycle 200-350 mg/week Every other day or 3x per week
Pitavastatin
1-4 mg/day / Once daily
Side Effects
Nandrolone
Suppression of natural testosterone production (profoundly suppressive, more so than testosterone alone)
Water retention and bloating (less than testosterone at equianabolic doses)
Erectile dysfunction and reduced libido without concurrent testosterone ('deca dick')
Increased appetite and weight gain
Mild acne and oily skin (less pronounced than testosterone)
Elevated hematocrit and hemoglobin (erythrocytosis)
Injection site pain or discomfort
Mild mood changes (some users report increased emotional sensitivity)
Pitavastatin
Myalgia and muscle discomfort (approximately 3-5% of users) — generally mild and less frequent than with lipophilic statins
Headache
Minimal liver enzyme elevation — typically transient and clinically insignificant
Back pain
Constipation or diarrhea
Contraindications
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy (Category X - causes virilization of female fetus)
Nephrosis or the nephrotic phase of nephritis
Severe hepatic impairment
Hypercalcemia
Known hypersensitivity to nandrolone or any formulation components
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled heart failure or severe cardiovascular disease
Active liver disease or unexplained persistent elevations in hepatic transaminases
Known hypersensitivity to pitavastatin or any excipients
Pregnancy and breastfeeding (Category X — statins are teratogenic)
Concomitant use with cyclosporine (significantly increases pitavastatin levels via OATP1B1 inhibition)
Concomitant use with lopinavir/ritonavir or atazanavir/ritonavir combinations
Research Evidence
Nandrolone Pitavastatin
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest April 2005 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.